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Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years,
intensive research has been conducted in the pharmacogenetics of these drugs basedmainly on the retrospective register studies, but
only a handful of associations detected in these studies were replicated.The gene variants inCYP2C9,ABCC8/KCNJ11, and TCF7L2
were associated with the effect of sulfonylureas. CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9,
ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K+ channel which is a therapeutic target for sulfonylureas,
andTCF7L2 is a genewith the strongest associationwith type 2 diabetes. SLC22A1, SLC47A1, andATM gene variantswere repeatedly
associated with the response to metformin. SLC22A1 and SLC47A1 encodemetformin transporters OCT1 andMATE1, respectively.
The function of a gene variant nearATM gene identified by a genome-wide association study is not elucidated so far.The first variant
associated with the response to gliptins is a polymorphism in the proximity of CTRB1/2 gene which encodes chymotrypsinogen.
Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical
breakthroughs in this field in a near future.
1. Introduction
Type 2 diabetes (T2D) affects more than 5% of population
of the developed countries and its prevalence increases
worldwide [1]. The majority of patients with T2D start
their treatment with oral antidiabetic drugs that influence
two basic pathogenetic mechanisms in the development
of T2D—insulin resistance or defects of insulin secretion.
Beside glucose stimulated insulin secretion, more attention
in the recent years is devoted to incretin augmented insulin
secretion and new drugs were introduced in clinical practice
which enhance the actions of incretins.
There is a considerable variability in the effect of antidi-
abetic drugs. This variability is caused by nonbiological and
biological factors. Among nonbiological factors, psycholog-
ical and social factors play an important role. These include
compliance to medication, variable access to health care, and
physician prescribing practices which are dependent on both
international and national guidelines.
Biological factors are related to pharmacokinetics and
pharmacodynamics of drugs. Biological factors might be
nongenetic, such as the influence of intestinal, hepatic and
renal functions, or drug interactions predominantly on phar-
macokinetics of drugs. Pharmacogenetics focuses on the
study of genetic factors which influence the effect and side
effects of different drugs with the final aim of personalizing
the treatment of T2D. While clear implications for clinical
practice based on pharmacogenetic knowledge exist only
for some forms of monogenic diabetes [2], this review will
focus on the more recent work undertaken to elucidate
pharmacogenetic mechanism in common type 2 diabetes.
2. Methodological Aspects of Pharmacogenetic
Studies in T2D
The optimal design of pharmacogenetic studies requires
attention to some keymethodological issues. Whilst the ideal
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study is a prospective genotype-blind study design with ade-
quate statistical power, these are very costly, time-consuming
and often require participation ofmultiple centers.Therefore,
the majority of studies published used retrospective data
retrieved from registers and databases. In the retrospective
studies, it is possible to achieve reasonable sample sizes for
pharmacogenetic studies, but it can be difficult to adjust
for all confounding variables as these may not have been
measured. However, as most confounding should not be
genotype dependent, this should not be a major issue.
With respect to the outcomes used in pharmacogenetic
studies, there are two main types of endpoints. Pathophys-
iological endpoints reflect the effect of gene variants on
insulin resistance or insulin secretion. Such studies may yield
novel knowledge on the role of different gene variants in the
pathogenesis of T2D, but their clinical applicability might
be limited. Thus, from the point of view of possible clinical
implications, endpoints such as reduction of HbA1c, fasting
plasma glucose, and postprandial plasma glucose are of the
highest importance. Among them, both an achievement of
therapeutic target of HbA1c<7% defined in guidelines and
a reduction in HbA1c seem to be the most appropriate
endpoints for pharmacogenetic studies in T2D [3].
Different factors may confound the relationship between
the studied gene variants and endpoints. When using achi-
evement ofHbA1c<7%or reduction inHbA1c as an endpoint,
the strongest confounder is the baseline level of HbA1c, as
it was shown in both the meta-analysis of clinical trials and
also in the individual pharmacogenetic studies [4, 5]. That
mean—if there is an imbalance in baseline HbA1c among the
genotypes—one could expect higher response in the patients
with higher baselineHbA1c values. On the other hand, higher
baseline HbA1c might also reflect the effect of the gene
variant on previous diabetes control. Thus, it is correct to
show rough (unadjusted) data alongwith themodels adjusted
for confounding variables. It is also important to take into
account whether the drug of interest is being used early
on in the disease process, or as add-on therapy later in the
disease, where there is less likely to be a large therapeutic
effect. Covariates that are usually taken into account such as
age, gender, BMI, and diabetes duration, are rarely significant
predictors of the drug effect in pharmacogenetic studies. If
the drug dose during the study is not constant, it is reasonable
to adjust for drug dosage. Since the majority of the oral
antidiabetic drugs are eliminated by the kidney, adjustment
for ameasure of renal function such asGFRor creatinine level
is also frequently needed. Furthermore, if retrievable from
databases, medication adherence and period of drug use are
useful covariates.
We selected studies discussed in this review taking into
account the above mentioned methodological aspects of
pharmacogenetic studies in patientswithT2D.Weperformed
a search in the MEDLINE and Web of Knowledge databases
using “pharmacogenetics OR pharmacogenomics” keyword
in combinations with the names of groups of antidiabetic
drugs or generic names of individual antidiabetic drugs.
In the present review, we will discuss the mechanisms of
associations between gene variants and the drug effect in the
healthy subjects, in cell lines and in the patients with T2D.
The studies which examined the effect of gene variants on the
indices of glucose control will be presented only when at least
100 patients with T2D are included in the study.
3. Pharmacogenetics of Insulin Secretagogues
Insulin secretagogues stimulate secretion of insulin from the
pancreatic 𝛽-cells. Sulfonylureas have been used for more
than a half-century, while nonsulfonylurea secretagogues
meglitinides (glinides) have been used for approximately the
last 15 years in the treatment of T2D. The most common
side effects of both groups of drugs are hypoglycemia and
weight gain. While previously sulfonylureas were considered
as first-line treatment in less obese patients with T2D, more
recent guidelines recommend both groups of drugs mainly
in combination therapy with metformin as a second-line
treatment [6].
3.1. Gene Variants Related to Pharmacokinetics of
Insulin Secretagogues
3.1.1. Cytochrome P450 Isoenzyme 2C9. Sulfonylureas are
metabolized in the liver primarily by cytochrome P450
isoenzyme 2C9 encoded by 𝐶𝑌𝑃2𝐶9 [7–10]. The major allele
of this gene is 𝐶𝑌𝑃2𝐶9∗1. Two common nonsynonymous
variants Arg144Cys (𝐶𝑌𝑃2𝐶9∗2) and Ile359Leu (𝐶𝑌𝑃2𝐶9∗3)
were identified [7]. Studies on healthy subjects showed that
the variant alleles are associated with increased plasma
concentration and decreased clearance of sulfonylureas after
oral administration [7, 10].
The first robust study to confirm association of
𝐶𝑌𝑃2𝐶9 variants with therapeutic response to sulfonylureas
was Genetics of Diabetes Audit and Research Tayside Study
(GoDARTS) which included 1073 patients treated with sulfo-
nylureas. The 6% of the population who were carriers of
two loss-of-function alleles (∗2/∗2 or ∗2/∗3 or ∗3/∗3) had a
0.5% greater reduction in HbA1c compared with wild-type
homozygotes (𝑃 = 0.003) and were 3.4 times more likely to
achieve on-treatment HbA1c<7% (𝑃 = 0.009) [5].
Further studies in patients with type 2 diabetes used indi-
rect endpoints of sulfonylurea effect such as prescribed dose
of sulfonylurea. Becker et al. analyzed 475 elderly patients
included in the Rotterdam study who started sulfonylurea
treatment. In the largest subgroup of patients treated with
tolbutamide (𝑛 = 172), there was a significant difference
in daily prescribed dose observed between genotypes. While
the prescribed dose of tolbutamide increased in the carriers
of ∗1/∗1, ∗1/∗2, or ∗2/∗2 genotypes, there was very little
tolbutamide dose increase in patients with ∗1/∗3 or ∗2/∗3
genotypes (𝑃 = 0.009) [11]. In a similar performed analysis
from a different Dutch group which analyzed data from
207 incident sulfonylurea users, a trend towards lower stable
glimepiride dose (𝑃 = 0.07) was observed in the carriers of
the 𝐶𝑌𝑃2𝐶9∗3 allele [12].
Studies in healthy volunteers showed that variants in
CYP2C9 influence also pharmacokinetics of nonsulfonylurea
secretagogue nateglinide [13], while variant in CYP2C8 is
associated with pharmacokinetics of repaglinide [14]. Phar-
macokinetics of both of these glinide drugs is also influenced
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by variant 521T>C in SLCO1B1, the gene encoding organic
anionic transporter B1 (OATPB1) [15].
3.2. Gene Variants Related Pharmacodynamics of Insulin
Secretagogues. The ATP-sensitive potassium (KATP) channel
plays crucial role in glucose stimulated insulin secretion. In
physiologic condition, ATP produced by glucose oxidation
in mitochondria leads to closure of KATP channel with
subsequent depolarization of 𝛽-cell membrane, increased
influx of calcium ions, and subsequent release of presyn-
thesized insulin from the 𝛽-cell. Insulin secretagogues (both
sulfonylureas and glinides) act by inducing KATP channel
closure by binding on its constituting proteins. The inner
pore of the KATP channel is constituted by four molecules of
potassium inward rectifier 6.2 (Kir6.2) while the outside part
is created by four molecules of sulfonylurea receptor 1 (SUR1)
[16].
Two sulfonylurea binding sites were identified on the
KATP channel. The A-site is exclusively part of the SUR1 sub-
unit whereas the B-site resides both on SUR1 and Kir6.2 sub-
units [17]. Sulfonylurea derivatives, chlorpropamide, tolbu-
tamide, and gliclazide, as well as nateglinide and mitiglinide,
bind exclusively to the A-site. Repaglinide binds exclusively
to the B-site, while glibenclamide, glipizide, and glimepiride
are AB-site binding drugs [18, 19].
Mutations in genes encoding KATP channel proteins—
KCNJ11 (encoding Kir6.2) and ABCC8 (encoding SUR1)—
lead to neonatal diabetes mellitus. Breakthrough pharmaco-
genetic studies showed that sulfonylureas are able to correct
the defect caused by KCNJ11 and ABCC8mutations resulting
in patients (believed previously to have type 1 diabetes) being
able to transition from long-term insulin therapy to sulfony-
lurea treatment [20, 21]. Thus, common variants in KCNJ11
and ABCC8 were logical selection also for pharmacogenetic
studies in type 2 diabetes.
3.2.1. Kir6.2 and SUR1. Nonsynonymous common variants
E23K in KCNJ11 and S1369A in ABCC8 were mostly studied
in pharmacogenetic studies with insulin secretagogues.These
two variants are in strong linkage disequilibrium so that
any association signal from these two polymorphisms is
genetically indistinguishable [22].
The most robust study which showed an association of
ABCC8 S1369A polymorphism with glycemic control was
done in Chinese population. The study included 661 patients
whowere genotyped for 25 single nucleotide polymorphisms.
KCNJ11 rs5210 (different from E23K) and ABCC8 S1369A
polymorphisms were significantly associated with decrease
in FPG. Association analysis of ABCC8 S1369A with sulfony-
lurea responsewas replicated in an independent cohort of 607
patients. In the combined analysis of both cohorts, subjects
with a ABCC8 AA genotype had a significantly greater
decrease in FPG (𝑃 < 0.001) and a 2-hour plasma glucose
(𝑃 < 0.003), but only a borderline decrease in HbA1c (1.7
versus 1.4%, 𝑃 = 0.06), in comparison with patients with SS
genotype [23]. Lack of significance in HbA1c level reduction
can be explained by relatively short 8-week duration of study,
during which full effect of treatment on reduction in HbA1c
level was not observed. Similar association was found by
another Chinese group which evaluated glycemic response
to 8-week gliclazide treatment. In a group of 115 patients
with T2D, a greater reduction in HbA1c in response to 8-
week gliclazide treatment in the carriers of the A-allele (SA
and AA) compared to homozygous carriers of the S-allele
(1.60 ± 1.39 versus 0.76 ± 1.70%, 𝑃 = 0.044) was observed
after adjustment for baseline HbA1c [24].
In Caucasian population, the association betweenKCNJ11
E23K and sulfonylurea efficacy was observed in the study
of Javorsky et al. which included 101 patients treated with
sulfonylurea after metformin monotherapy failure. In the
dominant model, the carriers of the K-allele had higher
reduction in HbA1c after 6-month therapy in comparison
with EE homozygotes (1.04 ± 0.10 versus 0.79 ± 0.12%, 𝑃 =
0.036) [25].
Previously, two studies did not find such association in
Caucasian population. In the United Kingdom Prospective
Diabetes Study (UKPDS) population, a group of 363 patients
primarily assigned to sulfonylurea treatment was analyzed.
No significant relationship was found between two KCNJ11
polymorphisms (E23K and L270V) and the response to
sulfonylurea. The evaluated outcome was based on two mea-
surements of FPG within the first year of treatment, but not
on HbA1c measurements [26]. Since titration of sulfonylurea
dose was carried out in the UKPDS, this may have con-
founded the response phenotype. Another study performed
in a group of 525 Italian patients showed that the carriers of
K-allele had significantly higher probability of secondary sul-
fonylurea failure. In that study, secondary sulfonylurea failure
was defined as not achieving FPG<300mg/dL (16.7mmol/L)
on-treatment with combination of sulfonylurea as the first-
choice drug andmetformin as an add-on drug [27].Thus, this
study reported the failure of the combination of sulfonylurea
with metformin, rather than the failure of sulfonylurea
treatment itself.
Another study in Chinese population examined the asso-
ciation between KCNJ11 E23K and therapeutic response to
repaglinide. He et al. found in a group of 100 patients treated
for 24 weeks with repaglinide that the decrease in HbA1c was
higher in patients with EK and KK genotypes than in EE
homozygotes (EE: 1.52 ± 1.03%, EK: 2.33 ± 1.53%, and KK:
2.65 ± 1.73%, 𝑃 = 0.022) [28]. The authors did not adjust
the decrease in HbA1c for the baseline levels; thus, it is not
possible to exclude that this effect was driven by an effect of
the E23K variant on baseline HbA1c.
Clinical studies showed higher efficacy of sulfonylurea
treatment in risk allele carriers suggesting that, in line with
the studies in neonatal diabetes, sulfonylureas and possibly
also glinides are able to correct the defect in insulin secretion
by binding to the proteins of the KATP channel resulting in its
closure. Studies in cell lines transfected by cloned channels
with KCNJ11 K23-ABCC8 A1369 haplotype shed some light
on observed differences among different sulfonylureas and
glinides to affect insulin secretion in carriers of risk haplo-
type. K23/A1369 carriers were more sensitive to inhibition
of KATP channel by gliclazide and mitiglinide in comparison
with E23/S1369 haplotype carriers. In contrast, E23/S1369
carriers were more sensitive to glimepiride, chlorpropamide,
and tolbutamide, whilst there was no difference in KATP
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channel sensitivity between the two haplotypes for gliben-
clamide, glipizide, repaglinide, and nateglinide [18, 19].
3.2.2. Transcription Factor 7-Like 2. Among more than 50
gene variants associated with T2D, the variants in tran-
scription factor 7-like 2 (TCF7L2) gene are the strongest
predictors of increased risk of developing type 2 diabetes, a
40% increased risk per allele [29, 30]. TCF7L2 is a nuclear
factorwhich binds𝛽-catenin,mediatesWnt-signaling, relates
to normal development of pancreas during embryogenesis,
and affects secretion of glucagon-like peptide 1 (GLP-1) by L-
cells in the small intestine [31]. Several studies observed that
carriers of the risk T-allele of TCF7L2 rs7903146 polymor-
phism have reduced insulin secretion [32, 33]. Mechanisms
whereby altered TCF7L2 production and/or function may
contribute to the development of type 2 diabetes are not
fully understood but likely include a decrease in 𝛽-cell mass,
impaired insulin processing or release, and impaired incretin
signaling in 𝛽-cells [34, 35].
GoDARTSwas the first pharmacogenetic study to address
the relationship between the TCF7L2 rs12255372 (G/T) and
rs7903146 (C/T) gene variants and response to sulphony-
lurea therapy in type 2 diabetic patients. In that study in
901 Scottish patients with type 2 diabetes, subjects with
the rs12255372TT genotype had approximately two times
higher probability for early sulphonylurea treatment failure
(HbA1c>7% within the period of 3–12 months after starting
sulphonylurea therapy) compared to those with the CC geno-
type. In a complementary approach, a linear regressionmodel
was used with minimal HbA1c during treatment within a
year after sulfonylurea initiation as the dependent variable.
The predicted HbA1c on-treatment was for rs1225372 GG
genotype 7.0%, while for TT genotype, it was 7.33%. Similar
results were observed for rs7903146 [36].
Results of this study were replicated by two study groups.
Javorsky´ et al. found in a group of 101 Slovakian patients that
the reduction in HbA1c after six months of sulphonylurea
therapy (ΔHbA1c) was significantly lower in the CT+TT
genotype group in comparison with the CC homozygotes
for rs7903146 genotype. The absolute difference in ΔHbA1c
between the two groups was 0.35% (𝑃 = 0.006) [37], that
is, very similar to the value observed in GoDARTS study.
In another study in a German population, Holstein et al.
included 179 patients treated with sulfonylureas and analyzed
sulfonylurea treatment failure after 6 months according
to rs7903146 genotypes. They found more than twice the
probability of sulfonylurea failure in TT homozygotes in
comparison with CC homozygotes (OR 2.09; 95% CI 1.02–
4.27, 𝑃 = 0.043). In this study, the adjustment for the baseline
HbA1c values was not performed [38].
4. Pharmacogenetics of Metformin
Metformin has been used for the treatment of type 2 dia-
betes mellitus since 1959 and is still the cornerstone in the
treatment of this disease. At physiological pH, metformin
is positively charged and therefore very hydrophilic, giving
it some interesting pharmacokinetic properties [39]. First,
metformin is not metabolized in the body but very efficiently
excreted in the urine.Therefore, the glucose lowering effect of
metformin is not affected by genetic variation inmetabolizing
enzymes. Second, metformin cannot diffuse through mem-
branes passively, but it is dependent on drug transporters for
the absorption, distribution, and elimination of metformin
[39]. The initial pharmacogenetic research focused on the
role ofmetformin transporterswhile themost extensive study
thus far is the genome-wide association study (GWAS).
4.1. Genome-Wide Association Study. In GWAS, Zhou et al.
genotyped more than 700,000 polymorphisms in 1,024 met-
formin users from the GoDARTs study [40]. They identified
14 polymorphisms in a locus containing the ATM gene
that were associated with the ability to reach the treatment
goal of an HbA1c<7%. The strongest association was with
the rs11212617 polymorphism. Participants had a 1.64 times
higher change of reaching the treatment goal for each minor
allele with a 𝑃 value of 1.9 × 10−7. The authors subse-
quently genotyped this polymorphism in two independent
populations (another GoDARTS population and the UKPDS
population) for replication. And in both populations, a
significant association was found with treatment response.
The combined effect was 1.35 times higher change of reaching
the treatment goal (𝑃 = 2.9 × 10−9) for each minor allele.
The secondary analysis was the association between this
polymorphism and the reduction in HbA1c, and a 0.11%
larger reduction in HbA1c per minor allele (𝑃 = 6.6 × 10−7)
was found in the three cohorts combined. In the replication
study by van Leeuwen et al., the rs11212617 polymorphism
was studied in three independent populations, the Diabetes
Care System (DCS)West-Friesland (𝑛 = 929), the Rotterdam
Study (𝑛 = 182), and the CARDS Trial (𝑛 = 254). They
used the same endpoint as was used in the initial GWAS by
Zhou et al. In the three populations, the combined odds ratio
was 1.24 with a 𝑃 value of 0.016. For the secondary endpoint,
the reduction in HbA1c per minor allele, no significant
association was found [41].
The rs11212617 polymorphism has also been genotyped
in the at-risk population of the aforementioned DPP trial.
However, Florez et al. describe that no association was found
between this polymorphism and the incidence of diabetes in
the participants randomized to metformin therapy [42].
4.2. Genes Related to Pharmacokinetics of Metformin
4.2.1. Organic Cation Transporters. Shu et al. were the first
to study the effect of genetic variation in the SLC22A1 gene
encoding the OCT1 transporter and the glucose lowering
effect of metformin both in animal model and in healthy vol-
unteers. They identified four polymorphisms in the SLC22A1
gene coding for a change in amino-acid sequence (R61C,
G401S, 420del, or G465R) and studied the association with
the glucose lowering effect. In the subjects carrying one or
more variant alleles, themetformin plasma levels were higher
and the glucose lowering effect during a glucose tolerance test
was impaired [43, 44]. InCaucasians, R61C and 420del are the
most important genetic variants, because the variant alleles
occur frequently and decrease transporter activity [45]. For
R61C, it has been shown that this variant strongly reduces
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OCT1 protein expression [46]. Tzvetkov et al. identified that
OCT1 beside the liver is also expressed on the apical side of
tubules and that healthy volunteers carrying 420del alleles in
OCT1 had an increased renal metformin clearance, due to a
decrease in reabsorbance [47].
Strikingly, in the largest study in subjects with T2D
performed by Zhou et al., no association was found [48]. In
this study, 1,531 type 2 diabetes mellitus patients participating
in the GoDARTS were included. Neither the R61C nor the
420del variant had a significant association with various
endpoints, including the maximum HbA1c reduction in the
18 months after start of metformin therapy and the ability to
reach a treatment target of HbA1c<7%.
Christensen et al. studied the effect of eleven polymo-
rphisms in various transporters including OCT1 on the
through plasma levels and the glucose lowering effect in 151
diabetes mellitus patients in whom metformin was added
to the previous insulin therapy. Patients with one or two
variant alleles of 420del had lower trough plasma levels. In
this study, two other polymorphisms, G401S and rs461473 in
an intronic region not coding for an amino-acid change, were
significantly associated with the glucose lowering effect after
start with metformin therapy [49].
Two other polymorphisms that have been described in
the OCT1 transporter are the rs622342 and the M408V poly-
morphisms. Becker et al. screened the SLC22A1 gene using
tagging polymorphisms and found that the rs622342 poly-
morphism was significantly associated with the glucose
lowering effect in 102 incident metformin users [50]. This
result has not been replicated thus far.TheM408V variant has
been associated with gastrointestinal side effects by Tarasova
et al. in 246metformin users [51].However, Shu et al. reported
that this genetic variation is not associated with reduction in
metformin transporter activity [43].
In Asians, the frequencies of R61C and 420del variants
are low and no polymorphisms in the SLC22A1 gene have
been described that occur frequently and have a reduced
transporter activity [45]. Several studies have suggested that
genetic variation in OCT2 has a more important role in
Asians than OCT1. OCT2, encoded by the SLC22A2 gene, is
expressed in the basolateral membrane of the renal epithelial
cells. In three studies in Asian populations, an association
between A270S and renal metformin clearance or plasma
lactate concentrations has been described [52–54]. An asso-
ciation between A270S and renal clearance was also found in
a study performed in the USA [55].
4.2.2. Multidrug and Toxin Extrusion Transporters. Metfo-
rmin is also a substrate for the multidrug and toxin extrusion
1 (MATE1) transporter. This transporter, encoded by the
SLC47A1 gene, is strongly expressed in the brush border
membrane of the kidney and the bile canaliculi in the
liver. It is believed to facilitate the excretion of compounds
such as metformin in the urine and bile. Becker et al.
were the first to identify that the tagging polymorphism
rs2289669 (G/A) was associated with the HbA1c lowering
effect in incident metformin users [56]. They subsequently
described an interaction with the rs622342 polymorphism
in the SLC22A1 gene, identified earlier by this group [57].
Jablonski et al. studied the effect of genetic variation in 40
candidate genes in 2,994 participants of the Diabetes Preven-
tion Program (DPP) study that were at risk for developing
diabetes mellitus [58]. They randomized the participants to
placebo, metformin, or lifestyle intervention and observed
the finding that the rs8065082 polymorphism is associated
with metformin response in the at-risk population treated
with metformin. Since this polymorphism is in tight linkage
disequilibrium with rs2289669 (𝑟2 ≈ 0,8) and the effect was
consistent in both studies, this is considered as a replication
of the previous findings of Becker et al. For the other
polymorphisms, no significant associations were found after
correction for multiple testing.
Also Tka´cˇ et al. identified in 148 incident metformin
users that the rs2289669 polymorphism is associated with
HbA1c reduction. The homozygous carriers of the minor A
allele had twofold reduction in HbA1c in comparison with
the G-allele carriers (1.10 ± 0.18% versus 0.55 ± 0.09%)
[59]. Stocker et al. studied the g.−66T>C polymorphism
in the promoter region of the SLC47A1 gene and found
that in healthy volunteers, the variant allele resulted in
lower glucose levels, and in 145 incident metformin users,
it resulted in an increased HbA1c lowering effect [60]. In a
subsequent study, they identified that this polymorphismwas
not associated with metformin disposition and that the effect
of the g.−66T>C polymorphism was larger in patients with
normal functioningOCT1 alleles [60].Most likely, the variant
allele associatedwith reduced expression of the SLC47A1 gene
results in higher hepatic plasma levels, due to reduced efflux
transporter activity. In patients with a reduced OCT1 influx
transporter activity, the hepatic plasma levels will be lower,
masking the effect of the SLC47A1 efflux polymorphism.
Also the MATE2 transporter, encoded by the SLC47A2
gene, is expressed at the brush border membrane of the
kidney.This transporter has two functional isoforms,MATE2
and MATE2-K. The g.−130G>A polymorphism is situated in
the basal promoter region of MATE2-K and results in an
increase in promoter activity. In the study by Choi et al., this
polymorphismwas associatedwith theHbA1c lowering effect
in 248 incident metformin users [61]. In the study by Stocker
et al., the renal clearance of metformin was diminished in
healthy volunteers carrying a variant allele and the glucose
lowering effect increased [60]. The effect of the g.−130G>A
polymorphism was influenced by the previously described
g.−66T>C polymorphism in the SLC47A1 gene. BothMATE1
and MATE2 are coexpressed at the apical membrane of the
kidney, possibly explaining their mutual effect [60].
5. Pharmacogenetics of Thiazolidinediones
The group of thiazolidinediones, including troglitazone, pio-
glitazone, and rosiglitazone,were introduced in the late 1990s.
These drugs are agonists of the peroxisome proliferator-acti-
vated receptor (PPAR-𝛾). Activation of this receptor regulates
the transcription of hundreds of genes, involved in lipid and
glucose metabolism. Effects associated with PPAR-𝛾 acti-
vation include decreased insulin resistance, decreased leptin
levels, and increased adiponectin levels. Troglitazone has
been withdrawn from the market worldwide due to liver
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injury and rosiglitazone has beenwithdrawn from themarket
in Europe due to an increased risk of cardiovascular events
and put under restrictions in the USA.
5.1. Genes Related to Pharmacokinetics of Thiazolidinediones
5.1.1. Cytochrome P450 2C8. Both pioglitazone and rosigli-
tazone are metabolized by the cytochrome P450 2C8 isoen-
zyme. The CYP2C8∗3 and ∗11 polymorphisms, coding for a
reduced functioning CYP2C8 enzyme, have been studied in
relation to the pharmacokinetics of these drugs.Three studies
associated these polymorphisms with increased pioglitazone
and rosiglitazone plasma levels [62–64] and one study did not
find such as association [65]. All four studies were performed
in healthy volunteers. Only in the study including patients
with type 2 diabetes treated by rosiglitazone from the South
Danish Diabetes Study cohort (𝑛 = 187), the association
between 𝐶𝑌𝑃2𝐶8∗3 variant and change HbA1c was studied.
The authors found reduced therapeutic response and a lower
risk for developing edemas in 𝐶𝑌𝑃2𝐶8∗3 carriers. In this
study rosiglitazone was added to the previous insulin treat-
ment and it was allowed to change the insulin dose during the
treatment which could have influenced the observed study
results [65].
5.2. Genes Related to Pharmacodynamics of
Thiazolidinediones
5.2.1. PPAR-𝛾. The obvious first choice in the pharmacoge-
netic research after thiazolidinediones was the PPAR-𝛾 gene.
One polymorphism in this gene, the P12A polymorphism
(rs1801282), was identified in 1997 and studied extensively in
the relation to the incidence of type 2 diabetes mellitus [66].
In ameta-analysis published in 2010, 66 studieswere included
and the risk of developing type 2 diabetes mellitus was 14 per-
cent lower for each minor allele of this polymorphism [67].
Three studies examined the association of this polymorphism
with the glucose lowering response of thiazolidinediones. In
the study by Hsieh et al. in 250 diabetes patients and the
study by Kang et al. in 198 diabetes patients, the alanine (A)
allele was associated with a stronger reduction in HbA1c and
fasting plasma glucose levels in pioglitazone and rosiglitazone
users, respectively [68, 69]. On the contrary, other studies
did not find an association between this polymorphism and
thiazolidinedione therapy. In the largest study thus far by
Florez et al., no association was found with insulin sensitivity
in 340 participants of the DPP study using troglitazone [70].
Blu¨her et al. (131 pioglitazone users) and Namvaran et al.
(101 pioglitazone users) did not find an association between
this polymorphism and HbA1c reduction, insulin sensitivity,
and therapeutic response, respectively [71, 72]. Whether
there is a true association between the P12A polymorphism
and response to thiazolidinedione therapy remains to be
determined.
5.2.2. PGC-1𝛼. The proliferator-activated receptor-𝛾 coacti-
vator-1𝛼 (PGC-1𝛼) is a regulator of PPAR-𝛾, and it is associ-
ated with the risk of developing diabetes. Both the T394T and
the G482S variants in this gene were related to response to
rosiglitazone therapy in the study byKang et al. in 241 patients
[69]. But in the study byHsieh et al., no associationwas found
with theG482S polymorphism in 250 pioglitazone users [68].
5.2.3. Adiponectin. The binding of thiazolidinediones to
PPAR-𝛾 regulates numerous other genes, and some of
these genes have been subject of pharmacogenetic research.
Adiponectin is the best studied gene that is regulated by
PPAR-𝛾. Three polymorphisms in this gene, − 11377C>G,
+45T>G, and +276G>T, were previously associated with
obesity development and the incidence of type 2 diabetes
mellitus, and the effect of these polymorphisms on thiazo-
lidinedione response was studied. In the study by Eun et al.,
the +45T>G and +276G>T polymorphisms were associated
with the change in HbA1c levels in 166 rosiglitazone users
[73].The association with the −11377C>Gpolymorphismwas
found in the study by Li et al. They found an association with
the change inHbA1c level after start of pioglitazone treatment
in 113 users, but no association was found with the +45T>G
polymorphism [74]. In the study by Namvaran et al., no
association was found between the +45T>G polymorphism
and response to pioglitazone in 101 users either [75].
6. Pharmacogenetics of Incretin Mimetics
The incretin effect is mediated by stimulation of insulin
secretion from pancreatic 𝛽-cells after ingestion of glucose or
mixed meals by intestinal hormones glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic peptide (GIP)
[76]. In a pilot study including 88 healthy individuals, it
was shown that two GLP-1 receptor (GLP1R) variants were
associated with altered 𝛽-cell sensitivity to GLP-1 infusion
[77]. Variation in the GIP receptor (GIPR) locus was reported
to influence the responses of the glucose and insulin to an oral
glucose challenge in a meta-analysis of nine GWAS which
included 15,234 nondiabetic subjects [78].
Besides the gene variants encoding GLP-1 and GIP recep-
tors, several T2D related gene variants were reported to be
associated with the incretin effect. Gene variants in TCF7L2
[79–81], voltage-gated potassium channel, KQT-like subfam-
ily, member 1 (KCNQ1) [82], and wolframin 1 (WFS1) [83]
were associated with decreased incretin secretion, decreased
sensitivity of GLP-1 or GIP receptors, or with decreased
suppression of glucagon secretion [84].
Since endogenous and exogenously applied GLP-1 is rapi-
dly degraded by dipeptidylpeptidase-4, two pharmacologic
approaches were developed to bypass this limitation and
to enhance the incretin effect: GLP-1 receptor antagonists
are resistant to DPP-4 and applied subcutaneously. Another
possibility is to inhibit DPP-4 by orally applied DPP-4
inhibitors (gliptins) [76].
6.1. Pharmacogenetics of Gliptins
6.1.1. Chymotrypsinogen. Until recently, no pharmacogenetic
study with incretin mimetics was published. In their recently
published study, ‘t Haart et al. used Metabochip (including
tests for approximately 186,000 SNPs that previously were
associated with metabolic or cardiovascular disease) and
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showed that three genetic loci (TMEM114, CHST3, and
CTRB1/2) had large effects on GLP-1 stimulated insulin
secretion during hyperinsulinemic clamp [85]. A pharmaco-
genetic study in two independent populations—Dutch DCS
West Friesland and GoDARTS—was performed. This study
included 173 patients treated by GLP-1 receptor antagonists,
in which no association of glycemic control after treatment
with any of the three gene variants was observed. Among 354
patients treated with gliptins, there was a significant associa-
tion between the rs7202877 T/G variant in the proximity to
CTRB1/2 gene encoding chymotrypsinogen and the response
to gliptin treatment. 10% patients carrying the minor G-allele
showed a significantly smaller decrease in HbA1c (in average
by 0.5%) in comparison to TT homozygotes [85].
7. Conclusions
There are a few areas where genetics is used to guide the-
rapy. This is becoming mainstream in the field of cancer
therapy where somatic mutations can determine the choice
of treatment. Out with the cancer setting, there are cur-
rently limited examples of clinical utility of genetics, with
probably the most accepted use being HLA genotyping
prior to commencing the antiretroviral, abacavir. The use of
genotyping abolishes hypersensitivity reactions to the drug
[86]. Diabetes is one of the few other disease areas where
genotype is used to guide therapy, albeit in rare monogenic
subtypes [20]. In this review, we have not focused on these
rare subtypes, but addressed the evidence for the role of
genetic variants in the pharmacogenetics of common type 2
diabetes. This field is progressing rapidly and with increasing
rigor. The most recent and promising advances have been
in the field of metformin therapy. Whilst at present, there
is no convincing clinical role for genotype led prescribing,
some of the organic cation transporter variants do offer
such promise, and the evidence is starting to accumulate
to sufficient level to justify a genotype led clinical trial. We
should recognize that pharmacogenetics can also be a useful
tool to understand drug mechanism, and this is highlighted
by the recent genome-wide association study that points to
a novel biological mechanism of action of metformin. With
increased collaboration between groups, establishment of
diabetes pharmacogenetics consortia, and with reduction in
costs of genomics, we anticipate that the next five years should
lead to some significant clinical breakthroughs in this field.
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